LONDON (13 February 2024) – Helios, a full-service global healthcare communications group, today announced that it has acquired Cogentia, a consulting group of HEOR and market access specialists who conduct research and data-led health analysis to help global pharmaceutical companies get their products to market and ensure patient uptake. The move will add another dimension to the capabilities of Helios Global Group, providing greater insights for clients around launch, and furthering the company’s mission of improving global health outcomes.
Andrew Minnock, CEO of Helios, said: “We’re incredibly excited to welcome Cogentia to the Helios group; this marks a significant step in the evolution of the company. Adding the hugely important area of HEOR and market access to our service offering aligns with our long-standing strategic goals and will add another layer to our global capabilities for clients.”
James Morris, Founder and Director at Cogentia, said: “Like Helios, Cogentia has a proven track record in innovation and growth. Bringing together two market leaders with aligned people-focused cultures, outstanding reputations for quality, and a commitment to creating strong client partnerships, will strengthen our market positioning, enhance our solutions, and create development opportunities for our teams. We’re looking forward to building on our collective successes over the coming years.”
Based in Cambridge, Cogentia is recognised as one of the UK’s leading market access consultancies, handling projects across numerous therapeutic areas in markets throughout the world.
NorthEdge, the lower mid-market private equity firm, supported the Helios strategic acquisition.
